DOCSLIB.ORG

Effect of Bradykinin and Eledoisin on Renal Function in the Dog Department of Internal Medicine (Prof. T. Torikai), Tohoku Unive

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Effect of Bradykinin and Eledoisin on Renal Function in the Dog Department of Internal Medicine (Prof. T. Torikai), Tohoku Unive Tohoku J. exp. Med., 1966, 89, 69-76 Effect of Bradykinin and Eledoisin on Renal Function in the Dog Takashi Furuyama,. Chikara Suzuki, Hiroshi Saito, Yozo Onozawa , Ryuji Shioji, Shozo Rikimaru, Keishi Abe and Kaoru Yoshinaga Department of Internal Medicine (Prof. T. Torikai), Tohoku University School of Medicine, Sendai Bradykinin (0.05, 0.1 and 0.2 ƒÊg/kg/min) and eledoisin (0.5, 1.0, 5.0 and 10.0ng/kg/min) were infused directly into the left renal artery of anesthetized dogs to demonstrate the effects of these peptides on renal function. Urinary volume, endogenous creatinine clearance (GFR), PAR clearance (RPF) and excretion of electrolytes were increased by infusion of these two peptides, but no constant change was observed in UK/U ,Va ratio. These data demonstrate that the increase in urinary output and electrolyte excretion is caused by the augmentation of tubular load of solutes which resulted from the increase of RPF and GFR. Tachy phylaxis was observed in dogs which received repeated infusions of bradykinin but this phenomenon was less distinct in the case of eledoisin. Bradykinin is a nonapeptide formed by the action of kinin-forming enzymes upon alpha-2-globulin fraction of the plasma and it plays an important role in the local control of blood flow to certain tissues. On the other hand, eledoisin isolated from the salivary gland of Eledone, is endecapeptide having powerful kinin-like activity2. Bradykinin and eledoisin administered intravenously produce reduction in systemic blood pressure because of vasodilator action of the peptides.2,3 Since the change in systemic blood pressure affects renal function in experiments with intravenous infusion of the peptides, it is difficult to reveal their direct action on the kidney. The experiments to be reported here were designed to determine changes in renal functions in response to bradykinin and eledoisin directly administered to the kidney. METHODS Five dogs were used for bradykinin infusion and 4 dogs for eledoisin. Mongrel dogs of both sexes, weighing from 9 to 15 kg were anesthetized with 30 mg/kg of sodium pentobarbital. Both ureters were exposed through a midline incision and catheterized with polyethylene tubings which were pushed up into the renal pelvis and tied securely in place. A polyethylene catheter was inserted from Received for publication, February 25, 1966. 69 10 T. Furuyama et at. the right femoral artery to the left renal artery and the tip of the catheter was placed so as to stay for approximately 1.5 cm in the left main renal artery. Another catheter was placed into the left femoral artery and it was connected to n electronic manometer to record the blood pressure. These procedures were performed at least 30 minutes before beginning experimental observations. The priming doses of p-aminohippurate (PAH) was given intravenously, and then PAH dissolved in isotonic glucose solution was infused at a constant rate. Synthetic bradykinin or eledoisin was dissolved in 5 per cent glucose solution and infused at a rate of 0.5 ml/min through the polyethylene catheter placed into the left renal artery. In the preliminary observations, isotonic glucose infused at a rate of 0.5 ml/min into the renal artery had no effect on the renal function. The rate of infusion of bradykinin was 0.05, 0.1 and 0.2 ,ƒÊg/kg/min and that of eledoisin 0.5, 1.0, 5.0 and 10.0 ng/kg/min, respectively. Each clearance period was 10 to 20 minutes, and the intervals of peptide infusion were approximately 10 minutes. PAH and creatinine concentrations were estimated using a Beckman DB spectrophotometer (Brod and Sirota, and Smith),9 plasma and urinary concentrations of sodium and potassium were analyzed by a flame-photometer and systemic blood pressure was continuously recorded using an electronic manometer (Nihon Koden Co. Ltd.). Fig. 1. Changes of systemic blood pressure produced by infusion of bradykinin (a) and eledoisin (b) into the left renal artery. Bradykinin and Renal Function 71 Fig. 2. Effects of the direct infusion of bradykinin into the renal artery on renal function. --•œ----•œ-- shows changes of renal function when bradykinin was infused in the order of 0.05, 0.1 and 0.2 ƒÊg/kg/min. RESULTS 1) Bradykinin infusion into the renal artery The infusion of bradykinin into the left renal artery at the rates of 0.05 to 0.2,ƒÊg/kg/min produced no change in the systemic blood pressure (Fig. 1 a) and in the functions of right kidney including urine volume, endogenous creatinine clearance (GFR), PAH clearance (RPF) and urinary excretion of sodium and potassium. In each experiment, urine volume increased on the infused side, and the augmented urinary volume fell immediately to the control level, when the infusion of bradykinin was discontinued. Moreover, RPF and GFR were 72 T I??Furuyama et al. Fig. 3. Changes of renal function when bradykinin was infused into the left renal artery in the order of 0.05, 0.1 and 0.2ƒÊg/kg/min. -•ü-•ü- shows renal function of the kidney on the infused side. --•œ----•œ-- shows that of the kidney on the control side . increased by infusion of bradykinin in all dogs. Sodium and potassium excretions were also increased, but the augmentation in potassium excretion was less than that in sodium excretion. With the exception of one dog, the extrac tion fraction of sodium (excreted Na/filtered Na) was increased in all dogs, but no constant change was observed in urinary K/Na ratio (Fig. 2). When bradykinin was infused in the order of 0.05, 0.1 and 0.2,ƒÊg/kg/min, the increment of the urinary volume at 0.2 ƒÊg/kg/min of bradykinin was less than that of 0.1,ƒÊg/kg/min (Fig. 3). In contrast, when bradykinin infusion was started from 0.2,ƒÊg/kg/min, then followed by 0.05 and 0.1,ƒÊg/kg/min, urinary volume was maximum at 0.2,ƒÊg/kg/min infusion (Fig. 4). Bradykinin and Renal Function 73 Fig. 4. Changes of renal function when bradykinin was infused into the left renal artery in the order of 0.2, 0.05 and 0.1 ƒÊg/kg/min. -•ü-•ü- shows renal function of the kidney on the infused side. --•œ----•œ-- shows that of the kidney on the control side. This phenomenon was also observed in RPF, GFR and electrolytes excretion, indicating a tachyphylactic action of bradykinin on renal function. 2) Eledoisin infusion into the renal artery The direct renal infusion of eledoisin at a rate of less than 5.0 ng/kg/min produced no change in the systemic blood pressure. But the systemic blood pressure was decreased by about 30 mmHg by 10.0 ng/kg/min of eledoisin (Fig. 1 b). Furthermore, when a dose of 20.0 jig/kg/min of eledoisin was infused, the blood pressure fell below 60 mmHg and an immediate cessation of urinary output was observed. 74 T. Furuyama et al. Fig. 5. Effects of the direct infusion of eledoisin into the renal artery on renal function. The effects of eledoisin on renal function were essentially similar to those demonstratedwith bradykinin infusion. Namely, the increaseof urinary volume, GFR, RPF, and electrolyte excretion was also observed during eledoisin infus ion, but no constant changewas obtained in extraction fraction of sodium and urinary K/Na ratio (Fig. 5). Since the minimal effective dose of eledoisin was 0.5 ng/kg/min, this peptide was more effective than bradykinin on the renal function. Tachyphylaxis was observed in one of three dogs, but we could not reveal this phenomenon in the other two dogs. COMMENT The present experiments demonstrated that urine flow, RPF, GFR and electrolyte excretion were increased by direct renal infusion of bradykinin. Bradykinin and Renal Function 75 Similar observations were reported by Heidenreich and his associates,4 Webster and Gilmore,5 and Barraclough and Mills.' Heidenreich concluded that the increase of urine volume and electrolyte excretion resulted from direct action of this peptide on the tubular cells. In our experiments, the increase of RPF and GFR was observed by direct renal infusion of bradykinin. The urinary volume and the sodium excretion were increased in pallalel with increase of GFR and RPF. Furthermore, extraction fraction of sodium was increased in four of five dogs by bradykinin infusion, but no constant change was observed in urinary K/Na ratio. These results indicate that the increase of glomerular filtration which results from vasodilator effect of bradykinin plays an important role in the mechanism of the augmentation of urinary volume and electrolyte excretion. Moreover, since the increase in medullary blood flow rate results in a decrease of the renal concentrating ability,7 it is possible that augmented medullary blood flow due to the vasodilator action of bradykinin may play a role in the increase of urinary volume. It is not absolutely necessary to assume a direct tubular effect of bradykinin to account for its influence on the renal function. If bradykinin was infused repeatedly, the renal response to the peptide, especially urinary output, was reduced in all cases. Namely, the effect of 0.1,ƒÊg/ kg/min of bradykinin was more powerful than that of 0.2 ,ƒÊg/kg/min when the peptide was administered in order of 0.05, 0.1 and 0.2 ,ƒÊg/kg/min. On the other hand, in case in which the peptide was administered in order of 0.2, 0.05 and 0.1 ,ƒÊg/kg/min, the most effective dose of bradykinin on renal function was 0.2 ,ƒÊg/kg/ min, and the effect of 0.1 ƒÊg/kg/min was practically equivalent to that of 0.05 ,ƒÊg/kg/min.
Load more

Recommended publications
  • Amylase Release from Rat Parotid Gland Slices C.L
    Br. J. P!harmnic. (1981) 73, 517-523 THE EFFECTS OF SUBSTANCE P AND RELATED PEPTIDES ON a- AMYLASE RELEASE FROM RAT PAROTID GLAND SLICES C.L. BROWN & M.R. HANLEY MRC Neurochemical Pharmacology Unit, Medical Research Council Centre, Medical School, Hills Road, Cambridge CB2 2QH 1 The effects of substance P and related peptides on amylase release from rat parotid gland slices have been investigated. 2 Supramaximal concentrations (1 F.M) of substance P caused enhancement of amylase release over the basal level within 1 min; this lasted for at least 40 min at 30°C. 3 Substance P-stimulated amylase release was partially dependent on extracellular calcium and could be inhibited by 50% upon removal of extracellular calcium. 4 Substance P stimulated amylase release in a dose-dependent manner with an ED50 of 18 nm. 5 All C-terminal fragments of substance P were less potent than substance P in stimulating amylase release. The C-terminal hexapeptide of substance P was the minimum structure for potent activity in this system, having 1/3 to 1/8 the potency of substance P. There was a dramatic drop in potency for the C-terminal pentapeptide of substance P or substance P free acid. Physalaemin was more potent than substance P (ED50 = 7 nM), eledoisin was about equipotent with substance P (ED5o = 17 nM), and kassinin less potent than substance P (ED50 = 150 nM). 6 The structure-activity profile observed is very similar to that for stimulation of salivation in vivo, indicating that the same receptors are involved in mediating these responses.
    [Show full text]
  • Sensory and Signaling Mechanisms of Bradykinin, Eicosanoids, Platelet-Activating Factor, and Nitric Oxide in Peripheral Nociceptors
    Physiol Rev 92: 1699–1775, 2012 doi:10.1152/physrev.00048.2010 SENSORY AND SIGNALING MECHANISMS OF BRADYKININ, EICOSANOIDS, PLATELET-ACTIVATING FACTOR, AND NITRIC OXIDE IN PERIPHERAL NOCICEPTORS Gábor Peth˝o and Peter W. Reeh Pharmacodynamics Unit, Department of Pharmacology and Pharmacotherapy, Faculty of Medicine, University of Pécs, Pécs, Hungary; and Institute of Physiology and Pathophysiology, University of Erlangen/Nürnberg, Erlangen, Germany Peth˝o G, Reeh PW. Sensory and Signaling Mechanisms of Bradykinin, Eicosanoids, Platelet-Activating Factor, and Nitric Oxide in Peripheral Nociceptors. Physiol Rev 92: 1699–1775, 2012; doi:10.1152/physrev.00048.2010.—Peripheral mediators can contribute to the development and maintenance of inflammatory and neuropathic pain and its concomitants (hyperalgesia and allodynia) via two mechanisms. Activation Lor excitation by these substances of nociceptive nerve endings or fibers implicates generation of action potentials which then travel to the central nervous system and may induce pain sensation. Sensitization of nociceptors refers to their increased responsiveness to either thermal, mechani- cal, or chemical stimuli that may be translated to corresponding hyperalgesias. This review aims to give an account of the excitatory and sensitizing actions of inflammatory mediators including bradykinin, prostaglandins, thromboxanes, leukotrienes, platelet-activating factor, and nitric oxide on nociceptive primary afferent neurons. Manifestations, receptor molecules, and intracellular signaling mechanisms
    [Show full text]
  • Intracerebroventricular Responses to Neuropeptide Y in the Antagonists
    British Journal of Pharmacology (1996) 117, 241-249 B 1996 Stockton Press All rights reserved 0007-1188/96 $12.00 9 Intracerebroventricular responses to neuropeptide y in the conscious rat: characterization of its receptor with selective antagonists Pierre Picard & 'Rejean Couture Department of Physiology, Faculty of Medicine, Universite de Montreal, C.P. 6128, Succursale Centre-Ville, Montreal, Quebec, Canada H3C 3J7 1 The cardiovascular and behavioural effects elicited by the intracerebroventricular (i.c.v.) administration of neuropeptide y (NPy) in the conscious rat were assessed before and 5 min after i.c.v. pretreatment with antagonists selective for NKI (RP 67,580), NK2 (SR 48,968) and NK3 (R 820) receptors. In addition, the central effects of NPy before and after desensitization of the NK, and NK2 receptors with high doses of substance P (SP) and neurokinin A (NKA) were compared. 2 Intracerebroventricular injection of NPy (10-780 pmol) evoked dose- and time-dependent increases in mean arterial blood pressure (MAP), heart rate (HR), face washing, head scratching, grooming and wet-dog shake behaviours. Similar injection of vehicle or 1 pmol NPy had no significant effect on those parameters. 3 The cardiovascular and behavioural responses elicited by NPy (25 pmol) were significantly and dose- dependently reduced by pretreatment with 650 pmol and 6.5 nmol of SR 48,968. No inhibition of NPy responses was observed when 6.5 nmol of RP 67,580 was used in a similar study. Moreover, the prior co-administration of SR 48,968 (6.5 nmol) and RP 67,580 (6.5 nmol) with or without R 820 (6.5 nmol) did not reduce further the central effects of NPy and significant residual responses (30-50%) remained.
    [Show full text]
  • Calcitonin Gene-Related Peptide Inhibits Local Acute Inflammation and Protects Mice Against Lethal Endotoxemia
    SHOCK, Vol. 24, No. 6, pp. 590–594, 2005 CALCITONIN GENE-RELATED PEPTIDE INHIBITS LOCAL ACUTE INFLAMMATION AND PROTECTS MICE AGAINST LETHAL ENDOTOXEMIA Rachel Novaes Gomes,* Hugo C. Castro-Faria-Neto,* Patricia T. Bozza,* Milena B. P. Soares,† Charles B. Shoemaker,‡ John R. David,§ and Marcelo T. Bozza{ *Laborato´rio de Imunofarmacologia, Departamento de Fisiologia e Farmacodinaˆmica, Fundacxa˜o Oswaldo Cruz, Rio de Janeiro 21045-900; †Centro de Pesquisas Goncxalo Muniz, Fundacxa˜o Oswaldo Cruz, Salvador/Bahia 40295-001; ‡Division of Infectious Diseases, Department of Biomedical Sciences, Tufts University School of Veterinary Medicine, North Grafton, Massachusettes; §Department of Tropical Public Health, Harvard School of Public Health, Boston, Massachusettes; {Laborato´rio de Inflamacxa˜o e Imunidade, Departamento de Imunologia, Instituto de Microbiologia, Universidade Federal do Rio de Janeiro 21941-590, Rio de Janeiro, Brazil Received 2 Sep 2004; first review completed 15 Sep 2004; accepted in final form 10 Aug 2005 ABSTRACT—Calcitonin gene-related peptide (CGRP), a potent vasodilatory peptide present in central and peripheral neurons, is released at inflammatory sites and inhibits several macrophage, dendritic cell, and lymphocyte functions. In the present study, we investigated the role of CGRP in models of local and systemic acute inflammation and on macrophage activation induced by lipopolysaccharide (LPS). Intraperitoneal pretreatment with synthetic CGRP reduces in approximately 50% the number of neutrophils in the blood and into the peritoneal cavity 4 h after LPS injection. CGRP failed to inhibit neutrophil recruitment induced by the direct chemoattractant platelet-activating factor, whereas it significantly inhibited LPS- induced KC generation, suggesting that the effect of CGRP on neutrophil recruitment is indirect, acting on chemokine production by resident cells.
    [Show full text]
  • Predicting Cell-Penetrating Peptides Using Machine Learning Algorithms and Navigating in Their Chemical Space
    www.nature.com/scientificreports OPEN Predicting cell‑penetrating peptides using machine learning algorithms and navigating in their chemical space Ewerton Cristhian Lima de Oliveira 1, Kauê Santana 2*, Luiz Josino 3, Anderson Henrique Lima e Lima 3* & Claudomiro de Souza de Sales Júnior 1* Cell‑penetrating peptides (CPPs) are naturally able to cross the lipid bilayer membrane that protects cells. These peptides share common structural and physicochemical properties and show diferent pharmaceutical applications, among which drug delivery is the most important. Due to their ability to cross the membranes by pulling high‑molecular‑weight polar molecules, they are termed Trojan horses. In this study, we proposed a machine learning (ML)‑based framework named BChemRF‑ CPPred (beyond chemical rules-based framework for CPP prediction) that uses an artifcial neural network, a support vector machine, and a Gaussian process classifer to diferentiate CPPs from non‑CPPs, using structure‑ and sequence‑based descriptors extracted from PDB and FASTA formats. The performance of our algorithm was evaluated by tenfold cross‑validation and compared with those of previously reported prediction tools using an independent dataset. The BChemRF‑CPPred satisfactorily identifed CPP‑like structures using natural and synthetic modifed peptide libraries and also obtained better performance than those of previously reported ML‑based algorithms, reaching the independent test accuracy of 90.66% (AUC = 0.9365) for PDB, and an accuracy of 86.5% (AUC = 0.9216) for FASTA input. Moreover, our analyses of the CPP chemical space demonstrated that these peptides break some molecular rules related to the prediction of permeability of therapeutic molecules in cell membranes.
    [Show full text]
  • In the Mammalian and Avian Gastrointestinal Tract
    Gut: first published as 10.1136/gut.15.9.720 on 1 September 1974. Downloaded from Gut, 1974, 15, 720-724 Cellular localization of a vasoactive intestinal peptide in the mammalian and avian gastrointestinal tract JULIA M. POLAK, A. G. E. PEARSE, J-C. GARAUD, AND S. R. BLOOM From the Department ofHistochemistry, Royal Postgraduate Medical School, Hammersmith Hospital, London, and the Institute of Clinical Research, Middlesex Hospital, London SUMMARY Immunohistochemical studies using an antiserum to a pure porcine vasoactive intestinal peptide, possessing no cross reactivity against the related hormones glucagon, secretin, and gastrin- inhibitory peptide, revealed a wide distribution of vasoactive intestinal peptide cells throughout the entire length of the mammalian and avian gut. The highest numbers of cells were present in the small intestine and more particularly in the large intestine in all species investigated. Three types of endocrine cell in the mammalian gut are sufficiently widely distributed to be con- sidered as the sites for production of vasoactive intestinal peptide. In the avian gut there are only two identifiable cell types. Sequential immunofluorescence and silver staining showed, in the bird, that the enterochromaffin (EC) cell was not responsible. This procedure could not be used in our mammalian gut samples but here serial section immunofluorescence for enteroglucagon and vasoactive intestinal peptide in- dicated that the two cells were not identical and that each was differently localized in the mucosa. These results leave the D cell of the Wiesbaden classification as the most likely site for the produc- tion of vasoactive intestinal peptide. The final identification must come from successful immune electron cytochemistry but this has not yet been achieved.
    [Show full text]
  • Back Matter (PDF)
    MOLECULAR PHARMACOLOGY 26:605-609 AUTHOR INDEX FOR VOLUME 26 A berg, Aaron, Watanabe, Kyoichi A., Fox, Jack J., and Philips, Frederick S. Metabolic Competition Studies of 2’-Fluoro-S-iodo-l- Albengres, Edith. See Urien, Riant, Brioude, and Tillement, 322 f3-D-arabinofuranosylcytosine in Vero Cells and Herpes Simplex Albuquerque, E. X. See Aracava, Ikeda, Daly, and Brooks, 304 Type 1-Infected Vero Cells, 587 See Ikeda, Aronstam, Daly, and Aracava, 293 Christie, Nelwyn T. See Cantoni, Swann, Drath, and Costa, 360 Ambler, S. Kelly, Brown, R. Dale, and Taylor, Palmer. The Chrivia, John. See Bolger, Dionne, Johnson, and Taylor, 57 Relationship between Phosphatidylinositol Metabolism and Mobili- Colacino, Joseph M. See Chou, Lopez, Feinberg, Watanabe, Fox, and zation of Intracellular Calcium Elicited by Alpha,-Adrenergic Recep- Philips, 587 tar Stimulation in BC3H-1 Muscle Cells, 405 Collins, Sheila, and Marletta, Michael A. Carcinogen-Binding Aracava, Y. Ikeda, S. R., Daly, J. W., Brookes, N., and Albu- Proteins: High-Affinity Binding Sites for Benzo[ajpyrene in Mouse querque, E. X. Interactions of Bupivacaine with Ionic Channels of Liver Distinct from the Ah Receptor, 353 the Nicotonic Receptor: Analysis of Single-Channel Currents, 304 Cooper, Dermot M. F. See Sadler and Mailer, 526 See Ikeda, Aronstam, Daly, and Albuquerque, 293 Corbett, Michael D. See Doerge, 348 Aronstam, R. S. See Ikeda, S. R. , Daly, J. W., Aracava, Y. , and Cormier, Ethel. See Jordan, Lieberman, Koch, Bagley, and Ruenitz, Albuquerque, E. X. , 293 272 Aub, Debra L. See Putney, McKinney, and Leslie, 261 Costa, Erminio. See Quach, Tang, Kageyama, Mocchetti, Guidotti, Meek, and Schwartz, 255 B Costa, Max.
    [Show full text]
  • Galanin, Neurotensin, and Phorbol Esters Rapidly Stimulate Activation of Mitogen-Activated Protein Kinase in Small Cell Lung Cancer Cells
    [CANCER RESEARCH 56. 5758-5764, December 15, 1996] Galanin, Neurotensin, and Phorbol Esters Rapidly Stimulate Activation of Mitogen-activated Protein Kinase in Small Cell Lung Cancer Cells Thomas Seufferlein and Enrique Rozengurt' Imperial Cancer Research Fund, P. 0. Box 123, 44 Lincoln ‘sinnFields, London WC2A 3PX, United Kingdom ABSTRACT and p44me@@k,aredirectly activated by phosphorylation on specific tyrosine and threonine residues by the dual-specificity MEKs, of Addition of phorbol 12,13-dibutyrate (PDB) to H 69, H 345, and H 510 which at least two isofonus, MEK-1 and MEK-2, have been identified small cell lung cancer (SCLC) cells led to a rapid concentration- and in mammalian cells (12—14).Several pathways leading to MEK acti time-dependent increase in p42―@ activity. PD 098059 [2-(2'-amino 3'-methoxyphenyl)-oxanaphthalen-4-one], a selective inhibitor of mitogen vation have been described. Tyrosine kinase receptors induce p42r@a@@@( activated protein kinase (MAPK) kinase 1, prevented activation of via a son of sevenless (SOS)-mediated accumulation of p2l@-GTP, p42maPk by PDB in SCLC cells. PDB also stimulated the activation of which then activates a kinase cascade comprising p74@', MEK, and p90r$k, a major downstream target of p42―@. The effect of PDB on both p42Jp44maPk (10, 11). Activation of seven transmembrane domain p42―@and p90rsk activation could be prevented by down-regulation of receptors also leads to p42@'@ activation, but the mechanisms in protein kinase C (PKC) by prolonged pretreatment with 800 aM PDB or volved are less clear, although both p2l@- and PKC-dependent treatment of SCLC cells with the PKC inhibitor bisindolylmaleinside (GF pathways have been implicated (15—20).Activated MAPKs directly 109203X), demonstrating the involvement ofphorbol ester-sensitive PKCS phosphorylate and activate various enzymes, e.g., p90@ (21, 22), and In the signaling pathway leading to p42 activation.
    [Show full text]
  • Five Decades of Research on Opioid Peptides: Current Knowledge and Unanswered Questions
    Molecular Pharmacology Fast Forward. Published on June 2, 2020 as DOI: 10.1124/mol.120.119388 This article has not been copyedited and formatted. The final version may differ from this version. File name: Opioid peptides v45 Date: 5/28/20 Review for Mol Pharm Special Issue celebrating 50 years of INRC Five decades of research on opioid peptides: Current knowledge and unanswered questions Lloyd D. Fricker1, Elyssa B. Margolis2, Ivone Gomes3, Lakshmi A. Devi3 1Department of Molecular Pharmacology, Albert Einstein College of Medicine, Bronx, NY 10461, USA; E-mail: [email protected] 2Department of Neurology, UCSF Weill Institute for Neurosciences, 675 Nelson Rising Lane, San Francisco, CA 94143, USA; E-mail: [email protected] 3Department of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, Annenberg Downloaded from Building, One Gustave L. Levy Place, New York, NY 10029, USA; E-mail: [email protected] Running Title: Opioid peptides molpharm.aspetjournals.org Contact info for corresponding author(s): Lloyd Fricker, Ph.D. Department of Molecular Pharmacology Albert Einstein College of Medicine 1300 Morris Park Ave Bronx, NY 10461 Office: 718-430-4225 FAX: 718-430-8922 at ASPET Journals on October 1, 2021 Email: [email protected] Footnotes: The writing of the manuscript was funded in part by NIH grants DA008863 and NS026880 (to LAD) and AA026609 (to EBM). List of nonstandard abbreviations: ACTH Adrenocorticotrophic hormone AgRP Agouti-related peptide (AgRP) α-MSH Alpha-melanocyte stimulating hormone CART Cocaine- and amphetamine-regulated transcript CLIP Corticotropin-like intermediate lobe peptide DAMGO D-Ala2, N-MePhe4, Gly-ol]-enkephalin DOR Delta opioid receptor DPDPE [D-Pen2,D- Pen5]-enkephalin KOR Kappa opioid receptor MOR Mu opioid receptor PDYN Prodynorphin PENK Proenkephalin PET Positron-emission tomography PNOC Pronociceptin POMC Proopiomelanocortin 1 Molecular Pharmacology Fast Forward.
    [Show full text]
  • The Role of Corticotropin-Releasing Hormone at Peripheral Nociceptors: Implications for Pain Modulation
    biomedicines Review The Role of Corticotropin-Releasing Hormone at Peripheral Nociceptors: Implications for Pain Modulation Haiyan Zheng 1, Ji Yeon Lim 1, Jae Young Seong 1 and Sun Wook Hwang 1,2,* 1 Department of Biomedical Sciences, College of Medicine, Korea University, Seoul 02841, Korea; [email protected] (H.Z.); [email protected] (J.Y.L.); [email protected] (J.Y.S.) 2 Department of Physiology, College of Medicine, Korea University, Seoul 02841, Korea * Correspondence: [email protected]; Tel.: +82-2-2286-1204; Fax: +82-2-925-5492 Received: 12 November 2020; Accepted: 15 December 2020; Published: 17 December 2020 Abstract: Peripheral nociceptors and their synaptic partners utilize neuropeptides for signal transmission. Such communication tunes the excitatory and inhibitory function of nociceptor-based circuits, eventually contributing to pain modulation. Corticotropin-releasing hormone (CRH) is the initiator hormone for the conventional hypothalamic-pituitary-adrenal axis, preparing our body for stress insults. Although knowledge of the expression and functional profiles of CRH and its receptors and the outcomes of their interactions has been actively accumulating for many brain regions, those for nociceptors are still under gradual investigation. Currently, based on the evidence of their expressions in nociceptors and their neighboring components, several hypotheses for possible pain modulations are emerging. Here we overview the historical attention to CRH and its receptors on the peripheral nociception and the recent increases in information regarding their roles in tuning pain signals. We also briefly contemplate the possibility that the stress-response paradigm can be locally intrapolated into intercellular communication that is driven by nociceptor neurons.
    [Show full text]
  • The Second Galanin Receptor Galr2 Plays a Key Role in Neurite Outgrowth from Adult Sensory Neurons
    416 • The Journal of Neuroscience, January 15, 2003 • 23(2):416–421 The Second Galanin Receptor GalR2 Plays a Key Role in Neurite Outgrowth from Adult Sensory Neurons Sally-Ann Mahoney,1 Richard Hosking,1 Sarah Farrant,1 Fiona E. Holmes,1 Arie S. Jacoby,2 John Shine,2 Tiina P. Iismaa,2 Malcolm K. Scott,3 Ralf Schmidt,4 and David Wynick1 1University Research Centre for Neuroendocrinology, Bristol University, Bristol BS2 8HW, United Kingdom, 2The Garvan Institute of Medical Research, Sydney, NSW 2010, Australia, 3Johnson & Johnson Pharmaceutical Research Institute, Spring House, Pennsylvania 19477-0776, and 4AstraZeneca R&D Montreal, Montreal, Quebec H4S 1Z9, Canada Expression of the neuropeptide galanin is markedly upregulated within the adult dorsal root ganglion (DRG) after peripheral nerve injury. We demonstrated previously that the rate of peripheral nerve regeneration is reduced in galanin knock-out mice, with similar deficits observed in neurite outgrowth from cultured mutant DRG neurons. Here, we show that the addition of galanin peptide signifi- cantly enhanced neurite outgrowth from wild-type sensory neurons and fully rescued the observed deficits in mutant cultures. Further- more,neuriteoutgrowthinwild-typecultureswasreducedtolevelsobservedinthemutantsbytheadditionofthegalaninantagonistM35 [galanin(1–13)bradykinin(2–9)]. Study of the first galanin receptor (GalR1) knock-out animals demonstrated no differences in neurite outgrowth compared with wild-type animals. Similarly, use of a GalR1-specific antagonist had no effect on neuritogenesis. In contrast, use of a GalR2-specific agonist had equipotent effects on neuritogenesis to galanin peptide, and inhibition of PKC reduced neurite outgrowth from wild-type sensory neurons to that observed in galanin knock-out cultures.
    [Show full text]
  • Evaluation of JNJ-54717793 a Novel Brain Penetrant Selective Orexin 1 Receptor Antagonist in Two Rat Models of Panic Attack Provocation
    fphar-08-00357 June 7, 2017 Time: 17:43 # 1 ORIGINAL RESEARCH published: 09 June 2017 doi: 10.3389/fphar.2017.00357 Evaluation of JNJ-54717793 a Novel Brain Penetrant Selective Orexin 1 Receptor Antagonist in Two Rat Models of Panic Attack Provocation Pascal Bonaventure1*, Christine Dugovic1, Brock Shireman1, Cathy Preville1, Sujin Yun1, Brian Lord1, Diane Nepomuceno1, Michelle Wennerholm1, Timothy Lovenberg1, Nicolas Carruthers1, Stephanie D. Fitz2, Anantha Shekhar2,3 and Philip L. Johnson4,3 1 Janssen Research & Development, LLC, San Diego, CA, United States, 2 Department of Psychiatry, Indiana University School of Medicine, Indianapolis, IN, United States, 3 Stark Neurosciences Research Institute, Indiana University School of 4 Edited by: Medicine, Indianapolis, IN, United States, Department of Anatomy and Cell Biology, Indiana University School of Medicine, Yukihiro Ohno, Indianapolis, IN, United States Osaka University of Pharmaceutical Sciences, Japan Orexin neurons originating in the perifornical and lateral hypothalamic area are Reviewed by: highly reactive to anxiogenic stimuli and have strong projections to anxiety and Kenji Hashimoto, Chiba University, Japan panic-associated circuitry. Recent studies support a role for the orexin system Karolina Pytka, and in particular the orexin 1 receptor (OX1R) in coordinating an integrative stress Jagiellonian University, Poland response. However, no selective OX1R antagonist has been systematically tested *Correspondence: Pascal Bonaventure in two preclinical models of using panicogenic stimuli that induce panic attack [email protected] in the majority of people with panic disorder, namely an acute hypercapnia-panic provocation model and a model involving chronic inhibition of GABA synthesis in Specialty section: This article was submitted to the perifornical hypothalamic area followed by intravenous sodium lactate infusion.
    [Show full text]